Allurion Technologies (Allurion Technologies) Risk Assessment

View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Allurion Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of Allurion Technologies's Risk Assessment

For the Medical Devices subindustry, Allurion Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allurion Technologies's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's Risk Assessment falls into.

Allurion Technologies (NYSE:ALUR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Allurion Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Allurion Technologies (Allurion Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Huron Drive, Natick, MA, USA, 01760

Website

Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.

Executives

Omar Ishrak	director	710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin	director	3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta	director, 10 percent owner	307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth	officer: Chief Financial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin	director	C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson	director	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon	officer: Chief Commercial Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur	director, officer: Chief Executive Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani	officer: Chief Medical Officer	11 HURON DRIVE, SUITE 200, NATICK MA 01760